Compare CYRX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYRX | SGMT |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 676.3M |
| IPO Year | 2008 | 2021 |
| Metric | CYRX | SGMT |
|---|---|---|
| Price | $16.84 | $11.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $13.31 | ★ $26.13 |
| AVG Volume (30 Days) | 440.9K | ★ 899.9K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,177,000.00 | $2,000,000.00 |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.61 | $4.50 |
| 52 Week High | $17.20 | $11.45 |
| Indicator | CYRX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.56 | 65.15 |
| Support Level | $14.55 | $6.60 |
| Resistance Level | $16.87 | N/A |
| Average True Range (ATR) | 0.55 | 0.53 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 86.56 | 91.61 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.